Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele, S; Peters, L; Sluzhynska, M; Yakovlev, A; Scherrer, A; Domingo, P; Gerstoft, J; Viard, J P; Gisinger, M; Flisiak, R; Bhaghani, S; Ristola, M; Leen, C; Jablonowska, E; Wandeler, Gilles; Stellbrink, H; Falconer, K; D'Arminio Monforte, A; Horban, A; Rockstroh, J K; ... (2019). Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV medicine, 20(4), pp. 264-273. Blackwell Science 10.1111/hiv.12711

[img] Text
Amele_et_al-2019-HIV_Medicine.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (233kB) | Request a copy

OBJECTIVES The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. METHODS Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. RESULTS Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). CONCLUSIONS In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Wandeler, Gilles

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1464-2662

Publisher:

Blackwell Science

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

30 Apr 2019 16:18

Last Modified:

30 Apr 2019 16:18

Publisher DOI:

10.1111/hiv.12711

PubMed ID:

30734998

Uncontrolled Keywords:

Europe HIV/HCV coinfection continuum of care sustained virological response treatment

BORIS DOI:

10.7892/boris.126469

URI:

https://boris.unibe.ch/id/eprint/126469

Actions (login required)

Edit item Edit item
Provide Feedback